Robert M. Janosky
Corporate Officer/Principal bei SATSUMA PHARMACEUTICALS, INC.
Profil
Robert M.
Janosky is currently the Chief Commercial Officer at Satsuma Pharmaceuticals, Inc. Prior to this, he worked as the VP of Business Development & Strategic Planning at DURECT Corp.
from 2016 to 2020.
He received his undergraduate degree from the University of Vermont and his MBA from the University of Rochester Simon Business School.
Aktive Positionen von Robert M. Janosky
| Unternehmen | Position | Beginn |
|---|---|---|
| SATSUMA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 05.03.2020 |
Ehemalige bekannte Positionen von Robert M. Janosky
| Unternehmen | Position | Ende |
|---|---|---|
| DURECT CORPORATION | Corporate Officer/Principal | 01.03.2020 |
Ausbildung von Robert M. Janosky
| University of Vermont | Undergraduate Degree |
| University of Rochester Simon Business School | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| DURECT CORPORATION | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Satsuma Pharmaceuticals, Inc.
 Satsuma Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Satsuma Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It develops novel therapeutic products for the acute treatment of migraines. Its product candidate, STS101, is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, or DHE, which is designed to be self-administered with a proprietary pre-filled, single-use, nasal delivery device. The company was founded by John Kollins on June 21, 2016 and is headquartered in Durham, NC. | Health Technology |
